Last reviewed · How we verify
R21/Matrix-M™
R21/Matrix-M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite.
R21/Matrix-M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite. Used for Malaria prevention in children and infants in endemic regions.
At a glance
| Generic name | R21/Matrix-M™ |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Recombinant protein subunit vaccine |
| Target | Plasmodium falciparum circumsporozoite protein (CSP) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
R21 is a recombinant circumsporozoite protein (CSP) antigen derived from P. falciparum, formulated with Matrix-M, an adjuvant that enhances immunogenicity. The vaccine stimulates both antibody and T-cell mediated immune responses to prevent malaria infection by targeting the parasite during its pre-erythrocytic stage in the liver.
Approved indications
- Malaria prevention in children and infants in endemic regions
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) (PHASE1)
- Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV (PHASE1)
- L9LS-R21 Interaction (PHASE2)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
- A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™ (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R21/Matrix-M™ CI brief — competitive landscape report
- R21/Matrix-M™ updates RSS · CI watch RSS
- University of Oxford portfolio CI